Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
April 20 2021 - 8:00AM
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical
company committed to developing medicines that transform the lives
of people with rare neurological diseases, today announced that it
has appointed Professor Robert S. Langer, Sc.D., as Chairman of its
Scientific Advisory Board.
“We welcome Professor Robert Langer, who has
joined Ovid as the new Chair of our Scientific Advisory Board,”
said Amit Rakhit, M.D., MBA, President, Ovid Therapeutics. “Bob
will help guide Ovid’s strategy to tackle opportunities and
scientific questions underlying disorders in the brain. His
perspective will be invaluable as we advance our pipeline of
next-generation therapeutics. In addition, he will play a pivotal
role as we expand our thought leadership on Ovid’s Scientific
Advisory Board.”
“The neurosciences are on the cusp of a
scientific and, hopefully, therapeutic revolution. Ovid has an
exciting approach to tackling the key questions that drive
scientific research and new medicines in the central nervous
system,” said Dr. Langer. “I am delighted to lead their Scientific
Advisory Board and look forward to helping drive advances in this
important area.”
Dr. Langer is one of 10 Institute Professors at
the Massachusetts Institute of Technology (MIT), and has written
over 1,500 scholarly articles. He is also the most cited engineer
in history (h-index 286, with over 338,000 citations according to
Google Scholar). He has served as the Chair of the U.S. Food and
Drug Administration’s Science Board, and has been recognized with
over 220 awards, including the United States National Medals of
both Science and Technology, and Innovation. Dr. Langer was named
as one of the 20 most important people in biotechnology by Discover
magazine and one of 15 innovators who will reinvent our future by
Forbes. TIME and CNN named him as one of the most important people
in America, and one of the 18 top people in science or medicine in
America. He was also recognized as one of the world’s 25 most
important individuals in biotechnology by Forbes and by BioWorld.
Dr. Langer holds 35 honorary doctorate degrees and has been elected
to the National Academies of Medicine, Engineering, Sciences, and
Inventors.
About Ovid Therapeutics
Ovid Therapeutics Inc. is a New
York-based biopharmaceutical company using its BoldMedicine®
approach to develop medicines that transform the lives of patients
with rare neurological disorders. We believe these disorders
represent an attractive area for drug development as the
understanding of the underlying biology has grown meaningfully over
the last few years and today represents a substantial opportunity
medically and commercially. Based on recent scientific advances in
genetics and the biological pathways of the brain, we aim to
identify, discover and acquire novel compounds for the treatment of
rare neurological disorders. We have built a deep knowledge of such
disorders, how to treat them and how to develop the clinically
meaningful endpoints required for development of a compound in
these disorders. We continue to execute on our strategy to build
this pipeline by discovering, in-licensing and collaborating with
leading biopharmaceutical companies and academic institutions.
Ovid’s emerging pipeline programs include OV329, a small molecule
GABA aminotransferase inhibitor for seizures associated
with Tuberous Sclerosis Complex and Infantile Spasms;
OV882, a short hairpin RNA therapy approach for Angelman syndrome;
OV815, a genetic therapy approach for KIF1A associated neurological
disorder; and other non-disclosed research targets. Additionally,
Ovid maintains a financial interest in OV935 which is now being
developed by Takeda. For more information on Ovid, please
visit www.ovidrx.com.
Contacts
Investors and Media:Ovid Therapeutics
Inc.Investor Relations & Public Relationsirpr@ovidrx.com
OR
Investors:Argot PartnersDawn
Schottlandt212-600-1902ovid@argotpartners.com
Media:Dan Budwick1ABdan@1abmedia.com
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ovid Therapeutics (NASDAQ:OVID)
Historical Stock Chart
From Apr 2023 to Apr 2024